SG11201903846TA - 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (cabp) - Google Patents

9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (cabp)

Info

Publication number
SG11201903846TA
SG11201903846TA SG11201903846TA SG11201903846TA SG11201903846TA SG 11201903846T A SG11201903846T A SG 11201903846TA SG 11201903846T A SG11201903846T A SG 11201903846TA SG 11201903846T A SG11201903846T A SG 11201903846TA SG 11201903846T A SG11201903846T A SG 11201903846TA
Authority
SG
Singapore
Prior art keywords
international
cabp
english
applicant
bacterial pneumonia
Prior art date
Application number
SG11201903846TA
Other languages
English (en)
Inventor
Evangelos L Tzanis
Paul Mcgovern
Original Assignee
Paratek Pharm Innc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paratek Pharm Innc filed Critical Paratek Pharm Innc
Publication of SG11201903846TA publication Critical patent/SG11201903846TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201903846TA 2016-11-01 2017-10-31 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (cabp) SG11201903846TA (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662416010P 2016-11-01 2016-11-01
US201662422843P 2016-11-16 2016-11-16
US201762480516P 2017-04-02 2017-04-02
US201762500611P 2017-05-03 2017-05-03
US201762514415P 2017-06-02 2017-06-02
PCT/US2017/059165 WO2018085216A1 (en) 2016-11-01 2017-10-31 9-aminomethyl minocycline compounds and use thereof in treating community-acquire bacterial pneumonia (cabp)

Publications (1)

Publication Number Publication Date
SG11201903846TA true SG11201903846TA (en) 2019-05-30

Family

ID=62076212

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201903846TA SG11201903846TA (en) 2016-11-01 2017-10-31 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (cabp)
SG10201913599RA SG10201913599RA (en) 2016-11-01 2017-10-31 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (cabp)

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201913599RA SG10201913599RA (en) 2016-11-01 2017-10-31 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (cabp)

Country Status (14)

Country Link
US (4) US10383884B2 (enExample)
EP (1) EP3534908B1 (enExample)
JP (3) JP7545803B2 (enExample)
CN (1) CN110087655A (enExample)
AU (1) AU2017353588B2 (enExample)
BR (1) BR112019008897A2 (enExample)
CA (1) CA3042514A1 (enExample)
MX (2) MX2019005070A (enExample)
MY (1) MY200446A (enExample)
PH (1) PH12019500960A1 (enExample)
RU (1) RU2019113715A (enExample)
SG (2) SG11201903846TA (enExample)
TW (4) TW202423450A (enExample)
WO (1) WO2018085216A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018085216A1 (en) * 2016-11-01 2018-05-11 Paratek Pharmaceuticals, Inc. 9-aminomethyl minocycline compounds and use thereof in treating community-acquire bacterial pneumonia (cabp)
US20200126094A1 (en) * 2018-10-19 2020-04-23 BioIDC, Inc. Medical research fraud detection system and software
PT117254B (pt) 2021-05-26 2024-04-18 Hovione Farm S A Método de síntese de compostos 9-aminometil tetraciclinas

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2990331A (en) 1956-11-23 1961-06-27 Pfizer & Co C Stable solutions of salts of tetracyclines for parenteral administration
US2980584A (en) 1957-10-29 1961-04-18 Pfizer & Co C Parenteral magnesium oxytetracycline acetic or lactic acid carboxamide vehicle preparation
US3062717A (en) 1958-12-11 1962-11-06 Pfizer & Co C Intramuscular calcium tetracycline acetic or lactic acid carboxamide vehicle preparation
US3165531A (en) 1962-03-08 1965-01-12 Pfizer & Co C 13-substituted-6-deoxytetracyclines and process utilizing the same
US3454697A (en) 1965-06-08 1969-07-08 American Cyanamid Co Tetracycline antibiotic compositions for oral use
NL6607516A (enExample) 1966-05-31 1967-12-01
DE1767891C3 (de) 1968-06-28 1980-10-30 Pfizer Verfahren zur Herstellung von wäßrigen arzneilichen Lösungen für die parenterale, perorale und lokale Anwendung mit einem Gehalt an einem Tetracyclinderivat
CA999855A (en) 1972-09-18 1976-11-16 Societa' Farmaceutici Italia S.P.A. Process for the preparation of tetracyclines derivatives in the 7 position
US3957980A (en) 1972-10-26 1976-05-18 Pfizer Inc. Doxycycline parenteral compositions
DE2442829A1 (de) 1974-09-06 1976-03-18 Merck Patent Gmbh Tetracyclische verbindungen und verfahren zu ihrer herstellung
US4018889A (en) 1976-01-02 1977-04-19 Pfizer Inc. Oxytetracycline compositions
US4126680A (en) 1977-04-27 1978-11-21 Pfizer Inc. Tetracycline antibiotic compositions
US5589470A (en) 1990-02-26 1996-12-31 Trustees Of Tufts College Reducing tetracycline resistance in living cells
US5064821A (en) 1982-11-18 1991-11-12 Trustees Of Tufts College Method and compositions for overcoming tetracycline resistance within living cells
US4806529A (en) 1982-11-18 1989-02-21 Trustees Of Tufts College, Tufts University Tetracycline activity enhancement
US4806372A (en) 1985-02-15 1989-02-21 Georgia Oil & Gas Co., Inc. Nitrite-free-curing of bacon and product thereof
US6756365B2 (en) 1991-11-06 2004-06-29 Trustees Of Tufts College Reducing tetracycline resistance in living cells
JP2002501026A (ja) 1998-01-23 2002-01-15 トルスティーズ オブ トゥフツ カレッジ 薬学的に活性の化合物及びその利用法
US6256365B1 (en) 1999-08-16 2001-07-03 Analogic Corporation Apparatus and method for reconstruction of images in a computed tomography system using oblique slices
US6849615B2 (en) 1999-09-14 2005-02-01 Paratek Pharmaceuticals, Inc. 13-substituted methacycline compounds
EP1666454B1 (en) 1999-09-14 2011-09-07 Trustees Of Tufts College Methods of preparing substituted tetracyclines with transition metal-based chemistries
US6500812B2 (en) 1999-09-14 2002-12-31 Paratek Pharmaceuticals, Inc. 13-substituted methacycline compounds
AU3105801A (en) 2000-01-24 2001-07-31 Trustees Of Tufts College Tetracycline compounds for treatment of cryptosporidium parvum related disorders
WO2001074761A1 (en) 2000-03-31 2001-10-11 Trustees Of Tufts College 7-and 9-carbamate, urea, thiourea, thiocarbamate, and heteroaryl-amino substituted tetracycline compounds
US6642270B2 (en) 2000-05-15 2003-11-04 Paratek Pharmaceuticals, Inc. 7-substituted fused ring tetracycline compounds
US20020132798A1 (en) 2000-06-16 2002-09-19 Nelson Mark L. 7-phenyl-substituted tetracycline compounds
AU2001268475A1 (en) 2000-06-16 2002-01-02 Trustees Of Tufts College 7-phenyl-substituted tetracycline compounds
US20040224927A1 (en) 2000-06-16 2004-11-11 Trustees Of Tufts College 7-N-substituted phenyl tetracycline compounds
US7094806B2 (en) 2000-07-07 2006-08-22 Trustees Of Tufts College 7, 8 and 9-substituted tetracycline compounds
US20050143353A1 (en) 2000-07-07 2005-06-30 Paratek Pharmaceuticals, Inc. 13-Substituted methacycline compounds
DK1679305T3 (da) 2000-07-07 2012-05-29 Tufts College 9-substituerede minocyclinforbindelser
EP1303479B1 (en) 2000-07-07 2011-04-06 Trustees Of Tufts College 7-, 8- and 9-substituted tetracycline compounds
KR101027625B1 (ko) 2000-07-07 2011-04-06 파라테크 파마슈티컬스, 인크. 7-치환 테트라사이클린 화합물
EP1241160A1 (en) 2001-03-13 2002-09-18 Glaxo Group Limited Tetracycline derivatives and their use as antibiotic agents
WO2002072532A1 (en) 2001-03-13 2002-09-19 Paratek Pharmaceuticals, Inc. 7, 9-substituted tetracycline compounds
AU2002250331A1 (en) 2001-03-13 2002-09-24 Paratek Pharmaceuticals, Inc. 7-pyrollyl tetracycline compounds and methods of use thereof
US7553828B2 (en) 2001-03-13 2009-06-30 Paratek Pharmaceuticals, Inc. 9-aminomethyl substituted minocycline compounds
CA2440757A1 (en) 2001-03-14 2002-09-19 Michael Draper Substituted tetracycline compounds as synergistic antifungal agents
JP2004530661A (ja) 2001-03-14 2004-10-07 パラテック ファーマシューティカルズ インコーポレイテッド 抗真菌剤としての置換テトラサイクリン化合物
US8088820B2 (en) 2001-04-24 2012-01-03 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for the treatment of malaria
US20060194773A1 (en) 2001-07-13 2006-08-31 Paratek Pharmaceuticals, Inc. Tetracyline compounds having target therapeutic activities
EP2332547A1 (en) 2001-07-13 2011-06-15 Paratek Pharmaceuticals, Inc. Tetracyclines for the treatment of inflammatory bowel disease
WO2003055441A2 (en) 2001-08-02 2003-07-10 Paratek Pharmaceuticals, Inc. Medicaments
WO2003023568A2 (en) 2001-09-10 2003-03-20 Paratek Pharmaceuticals, Inc. Computational method for determining oral bioavailability
EP2311796A1 (en) 2002-01-08 2011-04-20 Paratek Pharmaceuticals, Inc. 4-dedimethylamino tetracycline compounds
WO2003075857A2 (en) 2002-03-08 2003-09-18 Paratek Pharmaceuticals, Inc. Amino-methyl substituted tetracycline compounds
EA200401232A1 (ru) 2002-03-21 2005-12-29 Пэрэтек Фамэсьютикэлс, Инк. Замещенные соединения тетрациклина, фармацевтическая композиция и способ лечения чувствительного к тетрациклину состояния у субъекта
KR101089429B1 (ko) 2002-07-12 2011-12-07 파라테크 파마슈티컬스, 인크. 3, 10, 및 12ａ 치환된 테트라시클린 화합물
EP1562608A4 (en) 2002-10-24 2010-09-01 Paratek Pharm Innc METHOD OF USE OF SUBSTITUTED TETRACYCLINE COMPOUNDS FOR MODULATING THE RNA
WO2004091513A2 (en) 2003-04-10 2004-10-28 Paratek Pharmaceuticals, Inc. 9-aminomethyl substituted minocycline compounds
US20060287283A1 (en) 2003-07-09 2006-12-21 Paratek Pharmaceuticals, Inc. Prodrugs of 9-aminomethyl tetracycline compounds
KR101228706B1 (ko) 2003-07-09 2013-02-01 파라테크 파마슈티컬스, 인크. 치환된 테트라시클린 화합물
EP1716101A1 (en) 2004-01-15 2006-11-02 Paratek Pharmaceuticals, Inc. Aromatic a-ring derivatives of tetracycline compounds
EP2269978A3 (en) 2004-10-25 2011-09-21 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
CA2585418A1 (en) 2004-10-25 2006-05-04 Paratek Pharmaceuticals, Inc. 4-aminotetracyclines and methods of use thereof
AU2006210406C1 (en) 2005-02-04 2013-03-07 Paratek Pharmaceuticals, Inc. 11a, 12-derivatives of tetracycline compounds
CA2616224A1 (en) 2005-07-21 2007-02-01 Paratek Pharmaceuticals, Inc. 10-substituted tetracyclines and methods of use thereof
CA2639406A1 (en) 2006-01-24 2007-08-02 Paratek Pharmaceuticals, Inc. Methods of increasing oral bioavailability of tetracyclines
EP2537934A3 (en) 2006-05-15 2013-04-10 Paratek Pharmaceuticals, Inc. Methods of regulating expression of genes or of gene products using substituted tetracycline compounds
WO2008045507A2 (en) 2006-10-11 2008-04-17 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for treatment of bacillus anthracis infections
CA2673486C (en) 2006-12-21 2015-09-08 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for treatment of inflammatory skin disorders
EP3045449A1 (en) 2006-12-21 2016-07-20 Paratek Pharmaceuticals, Inc. Tetracycline derivatives for the treatment of bacterial, viral and parasitic infections
US7951789B2 (en) 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
WO2008127722A1 (en) 2007-04-12 2008-10-23 Paratek Pharmaceuticals, Inc. Methods for treating spinal muscular atrophy using tetracycline compounds
WO2008134048A2 (en) 2007-04-27 2008-11-06 Paratek Pharmaceuticals, Inc. Methods for synthesizing and purifying aminoalkyl tetracycline compounds
EA201070048A1 (ru) 2007-07-06 2010-10-29 Паратек Фармасьютикалс, Инк. Способы синтеза замещённых соединений тетрациклина (варианты)
BRPI0908951A2 (pt) 2008-03-05 2017-01-17 Paratek Pharm Innc compostos de minociclina e método de uso dos mesmos
PT2271348T (pt) 2008-03-28 2018-04-16 Paratek Pharm Innc Formulação de comprimido oral de composto de tetraciclina
EP2276342A4 (en) 2008-04-14 2012-02-22 Paratek Pharm Innc SUBSTITUTED TETRACYCLIN COMPOUNDS
TWI585071B (zh) 2008-05-19 2017-06-01 派洛泰克藥物股份有限公司 四環素化合物之甲苯磺酸鹽及同素異形體
PL3000805T3 (pl) 2008-08-08 2018-04-30 Tetraphase Pharmaceuticals, Inc. C7-fluoro podstawione związki tetracyklinowe
CA2980727C (en) * 2015-03-24 2023-09-19 Paratek Pharmaceuticals, Inc. Minocycline compounds for biodefense
CN109152789A (zh) * 2016-03-24 2019-01-04 帕拉特克药品公司 用于治疗和预防艰难梭菌感染的方法
CA3022936A1 (en) 2016-05-02 2017-11-09 Paratek Pharmaceuticals, Inc. 9-aminomethyl minocycline compounds and methods of use thereof in urinary tract infection (uti) treatment
TWI746610B (zh) 2016-08-03 2021-11-21 美商派瑞泰Ｓｐｖ２有限公司 9-胺甲基米諾四環素化合物及其用途
WO2018085216A1 (en) * 2016-11-01 2018-05-11 Paratek Pharmaceuticals, Inc. 9-aminomethyl minocycline compounds and use thereof in treating community-acquire bacterial pneumonia (cabp)

Also Published As

Publication number Publication date
AU2017353588A1 (en) 2019-06-20
US10835542B2 (en) 2020-11-17
US10383884B2 (en) 2019-08-20
WO2018085216A1 (en) 2018-05-11
MY200446A (en) 2023-12-26
MX2019005070A (es) 2019-09-23
EP3534908A4 (en) 2020-05-27
EP3534908B1 (en) 2025-07-09
WO2018085216A8 (en) 2018-06-21
TW202506134A (zh) 2025-02-16
JP2019532976A (ja) 2019-11-14
JP2025041746A (ja) 2025-03-26
US20250186465A1 (en) 2025-06-12
JP7545803B2 (ja) 2024-09-05
EP3534908C0 (en) 2025-07-09
MX2023004966A (es) 2023-05-24
US20210052609A1 (en) 2021-02-25
US20180153908A1 (en) 2018-06-07
US20200009162A1 (en) 2020-01-09
SG10201913599RA (en) 2020-02-27
RU2019113715A (ru) 2020-12-03
AU2017353588B2 (en) 2022-07-14
BR112019008897A2 (pt) 2019-08-13
JP2023058513A (ja) 2023-04-25
EP3534908A1 (en) 2019-09-11
TW202423450A (zh) 2024-06-16
CA3042514A1 (en) 2018-05-11
RU2019113715A3 (enExample) 2020-12-07
PH12019500960A1 (en) 2019-08-19
CN110087655A (zh) 2019-08-02
TW201821082A (zh) 2018-06-16
TW202535416A (zh) 2025-09-16

Similar Documents

Publication Publication Date Title
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201901658PA (en) Beta-lactamase inhibitor compounds
SG11201807176XA (en) TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201811151PA (en) Extracellular vesicle comprising a fusion protein having fc binding capacity
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201811003PA (en) Anti-pd-l1 antibodies and uses thereof
SG11201807720TA (en) Methods and systems for determining antibiotic susceptibility
SG11201909722WA (en) Methods and systems for high-throughput blood component collection
SG11201906891RA (en) Methods for the administration of certain vmat2 inhibitors
SG11201809082WA (en) Nlrp3 modulators
SG11201804086VA (en) Methods and compositions for nucleic acid analysis
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201811150WA (en) Ev-mediated delivery of binding protein-small molecule conjugates
SG11201900633XA (en) Piperidine cxcr7 receptor modulators
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201910134SA (en) Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
SG11201900845YA (en) Uses of il-13 antagonists for treating atopic dermatitis
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201809751XA (en) Egfr inhibitor compounds
SG11201906853QA (en) Anti-rsv monoclonal antibody formulation
SG11201810927QA (en) Pd-l1-specific antibodies and methods of using the same
SG11201907364WA (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
SG11201909807TA (en) Methods of manufacturing of niraparib